【美股财报】BioRestorative Therapies Inc 2024年度报告.pdf

Considerations for the use of anthelminthic therapy for the treatment of neurocysticercosis

Medical Rationale Supporting Patient Access To Novel Oncology Combination Therapies

Intra-Cellular Therapies Inc 2024年度报告

AK112 to validate its potential as next-generation IO therapy

Access to oncology combination therapies in Europe moving forward

Taysha Gene Therapies Inc 2024年度报告